Overview

Angiotensin-(1-7) Cardiovascular Effects in Aging

Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
Phase:
Early Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Treatments:
Angiotensin I (1-7)